CA
CLDX icon

Clearstead Advisors’s Celldex Therapeutics CLDX Stock Holding History

Clearstead Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261 Buy
+7
New +$226 ﹤0.01% 3108

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's CLDX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 7 shares worth $261. The stake represents ﹤0.01% of the portfolio and ranks #3108 among its holdings.

253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Clearstead Advisors held 7 shares of Celldex Therapeutics worth $261 as of Q2 2026.
  • Celldex Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3108 holding.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.